10x Genomics Acquires Proteintech Genomics to Bolster Proteomics; Thesis Remains Cautious

What happened

10x Genomics announced the acquisition of Proteintech Genomics, a division of Proteintech Group, to expand its high-plex proteomic capabilities for single cell and spatial applications. The deal aligns with TXG's strategy to strengthen its spatial biology portfolio, which has been a rare growth driver amid declining Chromium and instrument sales. Financial terms were undisclosed, and the acquisition likely adds modest near-term revenue while increasing integration complexity. Our master report highlights that TXG's core organic revenue is flat, instruments are collapsing, and recent profitability relies on non-recurring IP settlements—factors the acquisition does not address. Therefore, while strategically sensible, the deal does not change the unfavorable risk/reward skew at current valuations.

Implication

If TXG successfully integrates Proteintech Genomics and drives high-plex proteomics adoption, it could strengthen its spatial moat and support mid-teens consumables growth. However, we need to see evidence of revenue acceleration and margin stability without IP tailwinds before becoming constructive.

Thesis delta

The acquisition of Proteintech Genomics is a modest strategic positive that broadens TXG's proteomics offering but does not change the fundamental thesis. Core revenue is still flat-to-declining, instruments remain under pressure, and cash flow is propped up by non-recurring settlement proceeds. We maintain our sell rating with a $14 attractive entry, as the acquisition does not address the structural challenges facing the business.